Published in Br J Rheumatol on August 01, 1990
Pathogenesis of tendinopathies: inflammation or degeneration? Arthritis Res Ther (2009) 1.39
Fortnightly review: Corticosteroid injections in tendon lesions. BMJ (2001) 1.33
Low-level laser therapy (LLLT; 780 nm) acts differently on mRNA expression of anti- and pro-inflammatory mediators in an experimental model of collagenase-induced tendinitis in rat. Lasers Med Sci (2010) 1.14
'"The time has come" the walrus said ...'. Ann Rheum Dis (1992) 1.14
The use of a patient-based questionnaire (the Oxford Shoulder Score) to assess outcome after rotator cuff repair. Ann R Coll Surg Engl (2008) 0.88
TOL19-001 reduces inflammation and MMP expression in monolayer cultures of tendon cells. BMC Complement Altern Med (2015) 0.75
Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med (2000) 11.12
Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature (1980) 9.25
Osteoarthritis: new insights. Part 2: treatment approaches. Ann Intern Med (2000) 5.58
Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum (1995) 5.32
Radiographic patterns of osteoarthritis of the knee joint in the community: the importance of the patellofemoral joint. Ann Rheum Dis (1992) 4.79
Risk factors for the incidence and progression of radiographic knee osteoarthritis. Arthritis Rheum (2000) 4.52
EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis (2000) 4.37
Apatite deposition disease. A new arthropathy. Lancet (1976) 3.53
The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis (2008) 3.52
Determinants of disability in osteoarthritis of the knee. Ann Rheum Dis (1993) 3.16
Knee pain and disability in the community. Br J Rheumatol (1992) 3.15
Immunostimulant therapy with levamisole for rheumatoid arthritis. Lancet (1976) 3.07
Another look at osteoarthritis. Ann Rheum Dis (1979) 3.06
Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum (1995) 3.05
Radiographic assessment of the knee joint in osteoarthritis. Ann Rheum Dis (1992) 2.75
The importance of iron in rheumatoid disease. Lancet (1981) 2.44
Grading of films for sacro-iliitis in population studies. Ann Rheum Dis (1971) 2.06
Synovial fluid concentration of five different cytokines in rheumatic diseases. Ann Rheum Dis (1990) 2.04
Observations on the effect of immersion in Bath spa water. Br Med J (Clin Res Ed) (1986) 1.94
Yet more evidence that osteoarthritis is not a cartilage disease. Ann Rheum Dis (2006) 1.89
Intra-articular steroids in osteoarthritis. Rheumatol Rehabil (1980) 1.85
Synovial fluid crystals. Q J Med (1979) 1.77
A double-blind placebo-controlled trial of methylprednisolone pulse therapy in active rheumatoid disease. Lancet (1982) 1.77
An articular index for the assessment of osteoarthritis. Ann Rheum Dis (1981) 1.70
Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint. Br J Rheumatol (1995) 1.61
Apatite associated destructive arthritis. Br J Rheumatol (1984) 1.61
Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med (1989) 1.55
The identification of particulate matter in biological tissues and fluids. J Pathol (1977) 1.54
Effect of a specific iron chelating agent on animal models of inflammation. Ann Rheum Dis (1983) 1.52
Increased serum C reactive protein may reflect events that precede radiographic progression in osteoarthritis of the knee. Ann Rheum Dis (2000) 1.52
Pyrophosphate arthropathy: a study of metabolic associations and laboratory data. Ann Rheum Dis (1982) 1.50
Isolation and analysis of complement activating aggregates from synovial fluid of patients with rheumatoid arthritis using monoclonal anti-C3d antibodies. Ann Rheum Dis (1987) 1.49
Serum and synovial fluid osteocalcin (bone gla protein) levels in joint disease. Br J Rheumatol (1989) 1.48
Continuous and intermittent levamisole. A controlled trial. Ann Rheum Dis (1978) 1.45
99mTc HMDP bone scanning in generalised nodal osteoarthritis. II. The four hour bone scan image predicts radiographic change. Ann Rheum Dis (1986) 1.43
Factor VIII related antigen in the assessment of vasculitis. Ann Rheum Dis (1987) 1.43
Structural periodicity in human articular cartilage: comparison between magnetic resonance imaging and histological findings. Osteoarthritis Cartilage (1999) 1.41
Brown's syndrome: an unusual ocular complication of rheumatoid arthritis. Ann Rheum Dis (1990) 1.41
Wear of articular cartilage: the effect of crystals. Proc Inst Mech Eng H (1993) 1.40
Unmet need for joint replacement: a qualitative investigation of barriers to treatment among individuals with severe pain and disability of the hip and knee. Rheumatology (Oxford) (2003) 1.40
Serum amyloid-A protein concentration in rheumatoid arthritis and its role in monitoring disease activity. Ann Rheum Dis (1983) 1.39
Epidemiology of research into interventions for the treatment of osteoarthritis of the knee joint. Ann Rheum Dis (2000) 1.39
Mixed crystal deposition disease and osteoarthritis. Br Med J (1978) 1.39
Is progressive osteoarthritis an atheromatous vascular disease? Ann Rheum Dis (2005) 1.38
Pertussis vaccine pleurisy: a model of delayed hypersensitivity. Agents Actions (1976) 1.37
Clinical effectiveness of a rehabilitation program integrating exercise, self-management, and active coping strategies for chronic knee pain: a cluster randomized trial. Arthritis Rheum (2007) 1.34
Identification of pathological mineral deposits by Raman microscopy. Lancet (1991) 1.32
Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis. Ann Rheum Dis (1981) 1.30
Diurnal variation in the femoral articular cartilage of the knee in young adult humans. Magn Reson Med (2000) 1.28
Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan. Implications for pathogenesis. J Clin Invest (1994) 1.27
The treatment of gout with azapropazone: clinical and experimental studies. Eur J Rheumatol Inflamm (1981) 1.26
The use of beta-N-acetylglucosaminidase excretion to investigate renal disease in rheumatoid arthritis. Rheumatol Rehabil (1975) 1.25
Magnetic resonance imaging in osteoarthritis of the knee: correlation with radiographic and scintigraphic findings. Ann Rheum Dis (1991) 1.24
Treatment of vasospastic disease with prostaglandin E1. Br Med J (1980) 1.23
Outcomes of total knee replacement: a qualitative study. Rheumatology (Oxford) (2005) 1.23
D-penicillamine and immune complex deposition. Ann Rheum Dis (1979) 1.20
Effect of alignment of the medial tibial plateau and x-ray beam on apparent progression of osteoarthritis in the standing anteroposterior knee radiograph. Arthritis Rheum (2001) 1.19
Pulmonary and pleural lesions in rheumatoid disease. Br J Dis Chest (1978) 1.18
Pertussis vaccine oedema: an experimental model for the action of penicillamine-like drugs. Agents Actions (1976) 1.17
Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2). Br J Dermatol (1982) 1.17
No loss of cartilage volume over three years in patients with knee osteoarthritis as assessed by magnetic resonance imaging. Osteoarthritis Cartilage (2002) 1.17
Localised chondrocalcinosis in post-meniscectomy knees. Lancet (1982) 1.17
Aggregation of rat polymorphonuclear leucocytes in vitro. J Pharm Pharmacol (1980) 1.14
Enhanced oxidative response of polymorphonuclear leukocytes from synovial fluids of patients with rheumatoid arthritis. Autoimmunity (1988) 1.13
The role of particles in the pathogenesis of joint disease. Curr Top Pathol (1982) 1.13
Renal damage during treatment with antirheumatic drugs. Br Med J (1978) 1.13
Who should have priority for a knee joint replacement? Rheumatology (Oxford) (2002) 1.12
Economic evaluation of a rehabilitation program integrating exercise, self-management, and active coping strategies for chronic knee pain. Arthritis Rheum (2007) 1.09
Elevated serum C-reactive protein levels in osteoarthritis. Br J Rheumatol (1997) 1.08
Specificity of rheumatoid factors in relation to the disease state in rheumatoid arthritis. Ann Rheum Dis (1990) 1.07
Diuretic-induced gout in elderly women. Br J Rheumatol (1985) 1.07
The painful shoulder: can consultants agree? Br J Rheumatol (1996) 1.05
Activation of the alternative pathway of complement by monosodium urate monohydrate crystals and other inflammatory particles. Ann Rheum Dis (1983) 1.05
Absence of prostaglandin stimulated increase in acute phase proteins in systemic sclerosis. Lancet (1980) 1.04
Acute pseudogout: "crystal shedding" or acute crystallization? Arthritis Rheum (1981) 1.04
Levels of keratan sulfate in the serum and synovial fluid of patients with osteoarthritis of the knee. Arthritis Rheum (1991) 1.03
Human cartilage is degraded by rheumatoid arthritis synovial fluid but not by recombinant cytokines in vitro. Clin Exp Immunol (1991) 1.03
Salicylates and renal function in rheumatoid arthritis. Br Med J (1976) 1.03
Neuromuscular disorders in rheumatoid arthritis. A motor-point muscle biopsy study. Q J Med (1970) 1.02
Anticonvulsant intoxication precipitated by azapropazone. Postgrad Med J (1981) 1.02
Pyrophosphate arthropathy: a clinical and radiological study of 105 cases. Ann Rheum Dis (1982) 1.01
99mTc HMDP bone scanning in generalised nodal osteoarthritis. I. Comparison of the standard radiograph and four hour bone scan image of the hand. Ann Rheum Dis (1986) 1.01
Inflammatory responses to intradermal crystals in healthy volunteers and patients with rheumatic diseases. Rheumatol Int (1982) 1.01
Survival of calcium pyrophosphate crystals in stored synovial fluids. Ann Rheum Dis (1991) 0.99
Idiopathic haemorrhagic rupture of the shoulder in destructive disease of the elderly. Ann Rheum Dis (1986) 0.99
Pre-operative expectation predicts 12-month post-operative outcome among patients undergoing primary total hip replacement in European orthopaedic centres. Osteoarthritis Cartilage (2011) 0.98
Complicated polymyalgia. Br Med J (1977) 0.97
Apparent reduction of endogenous creatinine clearance by salicylate treatment. Br Med J (1976) 0.96
Factors affecting self-efficacy and pain intensity in patients with chronic musculoskeletal pain seen in a specialist rheumatology pain clinic. Rheumatology (Oxford) (2008) 0.96
Indolent Wegener's granulomatosis. Ann Rheum Dis (1983) 0.95
Evaluation of silicone as an artificial lubricant in osteoarthrotic joints. Br Med J (1971) 0.95
The effect of biological crystals and human serum on the rate of formation of crystals of monosodium urate monohydrate in vitro. Br J Rheumatol (1991) 0.95
Gender inequity in the provision of care for hip disease: population-based cross-sectional study. Osteoarthritis Cartilage (2010) 0.94
A tissue kallikrein in the synovial fluid of patients with rheumatoid arthritis. Ann Rheum Dis (1989) 0.94
Concentrations of glycosaminoglycans in synovial fluids and their relation with immunological and inflammatory mediators in rheumatoid arthritis. Ann Rheum Dis (1990) 0.93
Depressed degranulation response of synovial fluid polymorphonuclear leucocytes from patients with rheumatoid arthritis to IgG aggregates. Clin Exp Immunol (1990) 0.93
Sulindac in osteoarthrosis of the hip. Rheumatol Rehabil (1976) 0.93
Cholesterol crystals in shoulder synovial fluid. Br J Rheumatol (1987) 0.93
Mononuclear phagocytes in rheumatoid arthritis: Fc-receptor expression by peripheral blood monocytes. Ann Rheum Dis (1984) 0.92
Bone resorbing activity in synovial fluids in destructive osteoarthritis and rheumatoid arthritis. Ann Rheum Dis (1988) 0.92